Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.
|Number of pages||7|
|Journal||Current Opinion in Investigational Drugs|
|Publication status||Published - Apr 2004|
ASJC Scopus subject areas
- Drug Discovery